LONDON (Reuters) – An experimental drug from GlaxoSmithKline, designed to fight heart disease in a new way, failed to meet its main goal in the first of two big late-stage clinical studies, the company said on Tuesday.
Darapladib did, however, produce greater reductions in serious coronary events in some of the pre-defined secondary endpoints that GSK said required further analysis.
The once-daily pill, which is designed to prevent heart attacks and strokes by fighting clogged arteries in a completely different way from cholesterol-lowering drugs, has been viewed by analysts as a high-risk project.
(Reporting by Ben Hirschler)
- Health
- Pharmaceuticals & Drug Trials
- GlaxoSmithKline
- experimental drug
- heart attacks
YOUR COMMENT
